LGBTQ Americans Find Hope in Confirmation of Rachel Levine aarp.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aarp.org Daily Mail and Mail on Sunday newspapers.
Jamie Saxon, Office of Communications
April 26, 2021 noon
Amanda Satterthwaite, a 2010 Princeton graduate, knows a thing or two about the stress that comes at the end of the semester. One thing that I learned at Princeton that I really cherish now is how to fail and get right back up and finish the race. When you’re in it right now, you can’t appreciate that perspective, said Amanda Satterthwaite, a 2010 alumna and psychiatrist.
Photo courtesy of Amanda Satterthwaite
A psychiatrist at Vanderbilt University Medical Center, Satterthwaite completed her combined residency in internal medicine and psychiatry at the height of the pandemic at Tulane University School of Medicine including a stint in the intensive care unit of the VA hospital in New Orleans, which was packed with COVID-19 patients. But she said nothing compares to the pressure of her undergraduate years.
E-Mail
A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A.
Hemophilia is the most common severe inherited bleeding disorder in men. The disease affects 1 in 10,000 males worldwide and results from deficiency of blood clotting factor VIII (FVIII). Both children and adults with hemophilia A (80 percent of all hemophilia) receive treatment that involves infusing FVIII protein into the bloodstream. However, about 30 percent of them develop an immune response in the form of antibodies to FVIII (inhibitors), rendering treatment ineffective and increasing risk of mortality.
Tulane University will invest $5.7 million to significantly expand the Tulane University Translational Science Institute (TUTSI) into a university-wide center focused on finding better ways to diagnose, treat and prevent disease and translate scientific discoveries into medical practices that improve patient care and public health.
The institute will include new graduate degree programs to develop the next generation of clinical investigators, new training programs for clinical research coordinators and a shared “biobank” freezer farm to store and preserve patient samples for use by researchers across multiple studies and institutions. The institute will include other infrastructure improvements to support large-scale patient recruitment for clinical trials, data analysis and research study design.
Date Time
CHOP-led Research Study Identifies Key Target in Treatment-Resistant Hemophilia A
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.